Your browser doesn't support javascript.
loading
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Piotrowska, Zofia; Niederst, Matthew J; Karlovich, Chris A; Wakelee, Heather A; Neal, Joel W; Mino-Kenudson, Mari; Fulton, Linnea; Hata, Aaron N; Lockerman, Elizabeth L; Kalsy, Anuj; Digumarthy, Subba; Muzikansky, Alona; Raponi, Mitch; Garcia, Angel R; Mulvey, Hillary E; Parks, Melissa K; DiCecca, Richard H; Dias-Santagata, Dora; Iafrate, A John; Shaw, Alice T; Allen, Andrew R; Engelman, Jeffrey A; Sequist, Lecia V.
Affiliation
  • Piotrowska Z; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Niederst MJ; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Karlovich CA; Clovis Oncology, San Francisco, California.
  • Wakelee HA; Stanford Cancer Institute, Stanford University, Stanford, California.
  • Neal JW; Stanford Cancer Institute, Stanford University, Stanford, California.
  • Mino-Kenudson M; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Fulton L; Massachusetts General Hospital, Boston, Massachusetts.
  • Hata AN; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Lockerman EL; Massachusetts General Hospital, Boston, Massachusetts.
  • Kalsy A; Massachusetts General Hospital, Boston, Massachusetts.
  • Digumarthy S; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Muzikansky A; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Raponi M; Clovis Oncology, San Francisco, California.
  • Garcia AR; Massachusetts General Hospital, Boston, Massachusetts.
  • Mulvey HE; Massachusetts General Hospital, Boston, Massachusetts.
  • Parks MK; Massachusetts General Hospital, Boston, Massachusetts.
  • DiCecca RH; Massachusetts General Hospital, Boston, Massachusetts.
  • Dias-Santagata D; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Iafrate AJ; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Shaw AT; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Allen AR; Clovis Oncology, San Francisco, California.
  • Engelman JA; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Sequist LV; Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. lvsequist@partners.org.
Cancer Discov ; 5(7): 713-22, 2015 Jul.
Article in En | MEDLINE | ID: mdl-25934077
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Acrylamides / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Small Cell Lung Carcinoma / ErbB Receptors / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Discov Year: 2015 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Acrylamides / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Small Cell Lung Carcinoma / ErbB Receptors / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Discov Year: 2015 Document type: Article Country of publication: